Mind Medicine (MindMed) Inc
NASDAQ:MNMD

Watchlist Manager
Mind Medicine (MindMed) Inc Logo
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Watchlist
Price: 7.32 USD 3.39%
Market Cap: 536.8m USD
Have any thoughts about
Mind Medicine (MindMed) Inc?
Write Note

Mind Medicine (MindMed) Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mind Medicine (MindMed) Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Depreciation & Amortization
$1.3m
CAGR 3-Years
-2%
CAGR 5-Years
165%
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Depreciation & Amortization
$1.3B
CAGR 3-Years
-7%
CAGR 5-Years
-10%
CAGR 10-Years
-2%
Canopy Growth Corp
TSX:WEED
Depreciation & Amortization
CA$44.9m
CAGR 3-Years
-27%
CAGR 5-Years
-10%
CAGR 10-Years
73%
Sundial Growers Inc
NASDAQ:SNDL
Depreciation & Amortization
CA$64.9m
CAGR 3-Years
78%
CAGR 5-Years
134%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Depreciation & Amortization
$8m
CAGR 3-Years
-10%
CAGR 5-Years
24%
CAGR 10-Years
N/A
C
Curaleaf Holdings Inc
CNSX:CURA
Depreciation & Amortization
$180.8m
CAGR 3-Years
37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mind Medicine (MindMed) Inc
Glance View

Market Cap
536.8m USD
Industry
Pharmaceuticals

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-05-04. The firm focuses on discovering, developing and deploying psychedelic-inspired medicines and therapies to address addiction and mental illness. The firm's commercial drug development programs includes lysergic acid diethylamide (LSD) experiential therapy, 18-methoxycoronaridine (18-MC) opioid withdrawal, LSD microdosing, methylenedioxymethamphetamine (MDMA), and dimethyltryptamine (DMT). The firm's subsidiaries include Mind Medicine, Inc., HealthMode, Inc., MindMed Pty Ltd. and MindMed GmbH.

MNMD Intrinsic Value
2.22 USD
Overvaluation 70%
Intrinsic Value
Price

See Also

What is Mind Medicine (MindMed) Inc's Depreciation & Amortization?
Depreciation & Amortization
1.3m USD

Based on the financial report for Sep 30, 2024, Mind Medicine (MindMed) Inc's Depreciation & Amortization amounts to 1.3m USD.

What is Mind Medicine (MindMed) Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
165%

Over the last year, the Depreciation & Amortization growth was -58%. The average annual Depreciation & Amortization growth rates for Mind Medicine (MindMed) Inc have been -2% over the past three years , 165% over the past five years .

Back to Top